WASHINGTON – "Just make the drugs," doctors and patients frustrated with the nation's escalating drug shortages told biopharma Monday at an FDA workshop. Read More
ImmunoGen Inc. and partner Roche AG reported positive top-line data earlier this year from a Phase II trial testing T-DM1 in HER2-positive metastatic breast cancer patients, but observers had been waiting for the detailed progression-free survival (PFS) numbers. They got those figures Sunday during a presentation at the European Multidisciplinary Cancer Congress (EMCC) in Stockholm, Sweden. Read More
LONDON – The competitive potential of Alpharadin in treating bone metastases in patients with hormone-resistant prostate cancer was underlined in the first formal presentation of the Phase III study results, which showed the alpha-emitting radiotherapy not only met the primary endpoint of overall survival, but also all secondary endpoints, including a reduction in the number of bone fractures. Read More
Four years after splitting from Los Angeles-based CytRx Corp., RXi Pharmaceuticals Corp. is splitting again – this time, into two publicly traded companies. Read More
Mundipharma International Ltd., of Cambridge, UK, said new data from three Phase III studies showed that flutiform, a combination of fluticasone propionate, an inhaled corticosteroid and long-acting beta2-agonist formoterol fumarate improved lung function and effectively controlled symptoms across different asthma severities in adolescents and adults. Read More
IntelliCell BioSciences Inc., of New York, signed an exclusive supply and sale agreement with Millipore Corp., of Billerica, Mass., to sell and distribute Millipore's guava flow cytometry platform in the area of stromal vascular fraction. The collaboration will streamline the development of IntelliCell's tissue processing centers throughout the U.S. Read More
Peregrine Pharmaceuticals Inc., of Tustin, Calif., completed patient enrollment in its second randomized Phase II trial for bavituximab. The company said 66 patients with previously untreated genotype-1 hepatitis C virus infection were treated with 12 weeks of ribavirin in combination with bavituximab or pegylated interferon alpha-2a. Read More
